HistoSonics
Minneapolis, MN, United States · Healthcare · 292 employees
HistoSonics is a growth phase company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquefy and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The company’s new platform delivers personalized, tissue specific treatments with precisio
Funding history
- Funding Round — $250.0M — Oct 2025
- Funding Round — $102.0M — Aug 2024
- Series series d — $102.0M — Aug 2024
- Funding Round — $85.0M — Dec 2022
- Funding Round — $100.0M — Dec 2022
Recent signals
- Oct 16, 2025: Raised $250.0M
- Nov 18, 2024: Launched HistoSonics Launches the BOOMBOX Study to Evaluate Histotripsy for Liver Tumors.
- Oct 28, 2024: HistoSonics Awarded $90 Million Contract with Veterans Affairs for Tumor Destroying Histotripsy Systems
- Aug 15, 2024: Raised $102.0M
- Aug 15, 2024: Raised $102.0M in Series series d
- Dec 27, 2022: Raised $85.0M
- Dec 13, 2022: Raised $100.0M
- Jun 12, 2020: Raised $40.8M
See plans & pricing → Track HistoSonics’s funding, hiring, and signals — with verified contacts — on Fundz.